Histology and Embriology Department, School of Medical Sciences, Universidad Nacional de Rosario, Rosario, Argentina.
Rev Esp Enferm Dig. 2010 Jul;102(7):421-5. doi: 10.4321/s1130-01082010000700004.
The aim is to determine immunopathological modifications in rectal mucosa from rabbits after local challenge in ovalbumin (OVA) sensitized animals previously treated with montelukast.
thirty two rabbits divided into four groups: G1: normal; G2: subcutaneously OVA sensitized; G3: sensitized, locally OVA challenged and sampled 4 hours after challenge; and G4: sensitized, locally OVA challenged and treated 4 hours before challenge with montelukast (0.15 mg/kg). Specific anti-OVA IgE levels were evaluated by passive cutaneous anaphylaxis test (PCA). In each group 200 high microscopical power fields (HPF) were counted. Results were expressed as arithmetic mean and SE. Anti -CD4, CD5, micro chain monoclonal antibodies were used. Avidin biotin horseradish peroxidase system was used.
CD 4: G1: 8.3 +/- 0.06; G2: 13.4 +/- 0.08, G3: 8.25 +/- 0.06, G4: 11.8 +/- 0.02. CD 5: G1: 7.3 +/- 0.05; G2: 9.4 +/- 0.05, G3: 11.3 +/- 0.06, G4: 8.1 +/- 0.06. mu chain: G1: 10.4 +/- 0.06; G2: 3.8 +/- 0.02, G3: 6.0 +/- 0.10, G4: 2.2 +/- 0.10. In all cases, experimental groups (G3 vs. G4) presented statistical significant differences (p < 0.05). CD4+, CD5+ cells and mu chain+ decrease in experimental group (G4), probably due to lymphocyte migration inhibition to challenged mucosa. mu chain+ cell decrease could be based on B cell activation and expression of different surface immunoglobulins. Cells expressing mu chain decreased in G2 and G3 likely due to activation of B cells and subsequent expression of other immunoglobulin chains in cell surface.
We conclude that obtained data are important to elucidate immunopathology of local anaphylactic reaction in rectal mucosa from systemic sensitized animals after treatment with montelukast.
目的是确定在预先用孟鲁司特治疗的卵清蛋白(OVA)致敏动物局部挑战后,直肠黏膜的免疫病理学变化。
32 只兔子分为四组:G1:正常;G2:皮下 OVA 致敏;G3:致敏,局部 OVA 挑战,挑战后 4 小时取样;G4:致敏,局部 OVA 挑战,挑战前 4 小时用孟鲁司特(0.15mg/kg)治疗。通过被动皮肤过敏试验(PCA)评估特异性抗 OVA IgE 水平。在每组中计算 200 个高倍镜视野(HPF)。结果表示为算术平均值和 SE。使用抗-CD4、CD5、微链单克隆抗体。使用亲和素生物素辣根过氧化物酶系统。
CD4:G1:8.3±0.06;G2:13.4±0.08,G3:8.25±0.06,G4:11.8±0.02。CD5:G1:7.3±0.05;G2:9.4±0.05,G3:11.3±0.06,G4:8.1±0.06。μ 链:G1:10.4±0.06;G2:3.8±0.02,G3:6.0±0.10,G4:2.2±0.10。在所有情况下,实验组(G3 与 G4)之间均存在统计学显著差异(p<0.05)。实验组(G4)CD4+、CD5+细胞和 μ 链+减少,可能是由于淋巴细胞向 challenged 黏膜迁移受到抑制。μ 链+细胞减少可能基于 B 细胞激活和不同表面免疫球蛋白的表达。G2 和 G3 中 μ 链+细胞减少可能是由于 B 细胞激活和随后在细胞表面表达其他免疫球蛋白链所致。
我们得出的结论是,获得的数据对于阐明全身性致敏动物直肠黏膜局部过敏反应的免疫病理学具有重要意义,这些动物在接受孟鲁司特治疗后会发生反应。